pERC deliberated upon the cost effectiveness of ibrutinib compared with a treatment mix reflecting different local standards of care and noted there is currently no single standard of care in Canada in this clinical s - Ibrutinib - Document - PDFSEARCH.IO

First Page	Meta Content
	pERC deliberated upon the cost effectiveness of ibrutinib compared with a treatment mix reflecting different local standards of care and noted there is currently no single standard of care in Canada in this clinical s Add to Reading List Document Date: 2015-01-09 16:28:10 Open Document File Size: 679,74 KB Share Result on Facebook Country Canada / / Currency pence / USD / / IndustryTerm cancer treatment / / MedicalCondition cancers / refractory disease / leukemia / fatigue / cancer / disease / chronic lymphocytic leukemia / mantle cell lymphoma / illness / depression / infections / bulky disease / tumour / small lymphocytic lymphoma / lymphomas / / MedicalTreatment chemo / chemotherapy / immunotherapy / retreatment / / Organization Leukemia & Lymphoma Society of Canada / and Lymphoma / / Position chair / / ProvinceOrState Ontario / / Technology antibodies / chemotherapy / / SocialTag Lymphocytic leukemia Pharmacology B-cell chronic lymphocytic leukemia Orphan drugs Ofatumumab Leukemia Rituximab Mantle cell lymphoma End point of clinical trials Medicine

pERC deliberated upon the cost effectiveness of ibrutinib compared with a treatment mix reflecting different local standards of care and noted there is currently no single standard of care in Canada in this clinical sAdd to Reading List